A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer

BACKGROUND: Pancreatic cancer (PC) represents an aggressive disease with median overall survival (OS) of less than 1 year in the front-line setting. FOLFIRINOX and gemcitabine and paclitaxel (GP) are standard of care options for these patients; however, optimal selection of therapy is challenging. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kuei-Ting, Madison, Russell, Moore, Jay, Jin, Dexter, Fleischmann, Zoe, Newberg, Justin, Schrock, Alexa, Bhardwaj, Neeru, Lofgren, Katherine T, He, Jie, Frampton, Garrett, Hegde, Priti, Fabrizio, David, Pishvaian, Michael J, Ebot, Ericka, Singhi, Aatur, Sokol, Ethan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400136/
https://www.ncbi.nlm.nih.gov/pubmed/37354528
http://dx.doi.org/10.1093/oncolo/oyad178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400136/
https://www.ncbi.nlm.nih.gov/pubmed/37354528
http://dx.doi.org/10.1093/oncolo/oyad178

Ejemplares similares